PT Perdana Bangun Pusaka Tbk (KONI.JK)
Central Jakarta, ID
PT Perdana Bangun Pusaka Tbk, a subsidiary of PT Dasabina Adityasarana, was established in 1987 and is headquartered in Central Jakarta, Indonesia. The company specializes in the distribution and sale of photographic and medical products throughout Indonesia, operating via a network of retail stores and representative offices across 15 distinct geographical areas. Its comprehensive range of photographic offerings includes photo paper, chemical supplies, films, vinyl/flex banners, frames, and various other finished goods. The inventory also features color and inkjet papers, dye-sublimation printers, compact photofinishing labs (minilabs), and DNP media printing equipment. For the medical sector, PT Perdana Bangun Pusaka Tbk provides conventional supplies like auto processors, cassettes, grids, hangers, screens, X-ray films, and USG papers. Its digital medical imaging portfolio encompasses CR and DR systems, digital media products, LED viewers, scanners, and hard disk drives. Additionally, the company diversifies its business by leasing out office premises. Prior to April 1988, it operated under the name PT Konica Cemerlang.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -5.10% | -1.22% | -4.35% | +32.24% | +10.00% | +15.79% | +73.48% | +108.62% | +54.63% | +830.77% | +2,320.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Specialty Retail: +6.4%+4.1% Q1'26: +26.9% (vs Q1'25)
-
EPS growth Specialty Retail: +20.6%-6.3% Q1'26: +403.1% (vs Q1'25)
-
FCF margin FCF growth · Specialty Retail: +29.3%+6.0% Q1'26: +1.8% (vs Q1'25)
-
EBIT margin Specialty Retail: +5.4%+7.2% ★ Q1'26: +2.9% (vs Q1'25)
-
ROIC Specialty Retail: +6.5%+14.1% ★ Q1'26: +3.8% (vs Q1'25)
-
Share dilution Specialty Retail: +0.1%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Specialty Retail: 0.14×0.00× ★ Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 2/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-26 | B+ | 3/5 | 2/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-25 | B+ | 3/5 | 2/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-22 | B+ | 3/5 | 2/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-21 | B+ | 3/5 | 2/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-20 | B+ | 3/5 | 2/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-19 | B+ | 3/5 | 2/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-18 | B+ | 3/5 | 2/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-13 | B+ | 3/5 | 2/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-12 | B+ | 3/5 | 2/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-11 | B+ | 3/5 | 2/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-08 | B+ | 3/5 | 2/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-07 | B+ | 3/5 | 2/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-06 | B+ | 3/5 | 2/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-05 | B+ | 3/5 | 2/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-04 | B+ | 3/5 | 2/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-30 | B | 3/5 | 2/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-29 | B | 3/5 | 2/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-28 | B | 3/5 | 2/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-27 | B | 3/5 | 2/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-24 | B | 3/5 | 2/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-23 | B | 3/5 | 2/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-22 | B | 3/5 | 2/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-21 | B | 3/5 | 2/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-20 | B | 3/5 | 2/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-17 | B | 3/5 | 2/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-16 | B | 3/5 | 2/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Buntaram Gondomartono | Director of Finance & Independent Director | — | male |
| Lenny Kartika | Corporate Secretary | — | female |
| Rudi Lauw | Director of Marketing & Director | — | male |
| Sugianto Kolim | MD & President Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for KONI.JK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
